Tag

Eli Lilly And Company

All articles tagged with #eli lilly and company

finance2 years ago•3 min saved

FDA Delays Decision on Lilly's Alzheimer's Drug

Eli Lilly and Company's stock declined after the FDA delayed its decision on donanemab, an anti-amyloid beta antibody for early symptomatic Alzheimer's disease. The FDA will convene an advisory committee to discuss the drug's safety and effectiveness based on data from the TRAILBLAZER-ALZ 2 study. The decision, expected in the first quarter of 2024, has been postponed. Meanwhile, other companies like Biogen and GSK are also making strides in the Alzheimer's treatment space.

via Yahoo Finance|

#alzheimers-disease #donanemab #eli-lilly-and-company

health2 years ago•2 min saved

FDA Postpones Decision on Eli Lilly's Alzheimer's Drug, Prompting Special Committee Meeting

The Food and Drug Administration has unexpectedly delayed the approval of the Alzheimer's drug, donanemab, which was anticipated to be approved this month. Instead, the F.D.A. will convene a panel of independent experts to evaluate the drug's safety and efficacy, surprising both Alzheimer's experts and the drug's maker, Eli Lilly and Company. The decision will postpone any potential approval until at least later this year, with the company hoping for a swift action following the advisory committee's review.

via The New York Times|

#alzheimers #donanemab #drug-approval

healthcare2 years ago•8 min saved

Lilly's Acquisition of POINT Biopharma Boosts Oncology Capabilities with Next-Gen Radioligand Therapies

Eli Lilly and Company has announced its acquisition of POINT Biopharma, a radiopharmaceutical company focused on developing radioligand therapies for cancer treatment. Radioligand therapy involves delivering radiation directly to cancer cells, minimizing damage to healthy tissue. POINT's lead programs include a radioligand therapy for metastatic castration-resistant prostate cancer and another for gastroenteropancreatic neuroendocrine tumors. The acquisition will allow Lilly to expand its oncology capabilities and develop a pipeline of radioligand treatments for hard-to-treat cancers. The deal is expected to close by the end of 2023.

via PR Newswire|

#acquisition #cancer-treatment #eli-lilly-and-company

business2 years ago•8 min saved

Lilly's Acquisition of Sigilon Therapeutics Sends Shares Soaring

Eli Lilly and Company has announced its acquisition of Sigilon Therapeutics, a biopharmaceutical company focused on developing functional cures for acute and chronic diseases. The acquisition will enhance Lilly's efforts in developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The deal involves a tender offer of $14.92 per share in cash, with a potential total consideration of up to $126.56 per share. The transaction is expected to close in the third quarter of 2023.

via PR Newswire|

#acquisition #biopharmaceutical #business